Search research articles

お問い合わせ

JoVEについて

概要リーダーシップブログ JoVEヘルプセンター

著者向け

出版プロセス編集委員会範囲と方針査読よくある質問投稿

図書館員向け

推薦の声購読アクセスリソース図書館諮問委員会よくある質問

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments アーカイブ

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教員リソースセンター教員サイト

プライバシーポリシー

Search research articles

関連する実験動画

発達生物学について. ビットとピース.

Alessandro Minelli¹

¹Department of Biology, University of Padova, I 35131 Padova, Italy. alessandro.minelli@unipd.it

Science (New York, N.Y.)

|December 4, 2004

まとめ

No abstract available in PubMed .

関連する実験動画

関連する概念動画

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え

Same author

Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Cancers·2025

Same author

Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Cancers·2025

Same author

Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer.

JCO precision oncology·2025

Same author

Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort.

Clinical colorectal cancer·2025

Same author

Prognostic impact of depth of response and early tumour shrinkage in patients with <i>BRAF</i> <sup></sup> -mutated metastatic colorectal cancer treated with targeted therapy.

Therapeutic advances in medical oncology·2025

Same author

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.

Current oncology (Toronto, Ont.)·2024